Activated platelets may be a problem during PCI
Rapidly prevent them from entering the game
KENGREAL® (cangrelor) is the first and only intravenous P2Y12 receptor inhibitor
KENGREAL is a direct-acting P2Y12 receptor inhibitor specifically designed as an adjunct to PCI1,2
Meet Kenneth and Rafael—two potential patients in whomKENGREAL may be appropriate
KENGREAL pharmacokinetics are consistent across patients and not influencedby age, sex, renal function, hepatic function, or patient presentation.
IMPORTANT SAFETY INFORMATION
KENGREAL® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.
KENGREAL® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.
Drugs that inhibit platelet P2Y12 function, including KENGREAL®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL® than with clopidogrel. Bleeding complications with KENGREAL® were consistent across a variety of clinically important subgroups. Once KENGREAL® is discontinued, there is no antiplatelet effect after an hour.
The most common adverse reaction is bleeding.
KENGREAL® (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.